JP2014530877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530877A5 JP2014530877A5 JP2014537337A JP2014537337A JP2014530877A5 JP 2014530877 A5 JP2014530877 A5 JP 2014530877A5 JP 2014537337 A JP2014537337 A JP 2014537337A JP 2014537337 A JP2014537337 A JP 2014537337A JP 2014530877 A5 JP2014530877 A5 JP 2014530877A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- cells
- lymphoma
- relapsed
- refractory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 28
- 210000004027 cell Anatomy 0.000 claims 24
- 239000000090 biomarker Substances 0.000 claims 21
- 229940124291 BTK inhibitor Drugs 0.000 claims 19
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 17
- 230000002427 irreversible effect Effects 0.000 claims 15
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 14
- 238000011282 treatment Methods 0.000 claims 14
- 206010066476 Haematological malignancy Diseases 0.000 claims 11
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 11
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 11
- 230000035772 mutation Effects 0.000 claims 11
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 9
- 201000005787 hematologic cancer Diseases 0.000 claims 8
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 8
- 210000005259 peripheral blood Anatomy 0.000 claims 8
- 239000011886 peripheral blood Substances 0.000 claims 8
- 229960004641 rituximab Drugs 0.000 claims 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 201000003444 follicular lymphoma Diseases 0.000 claims 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 5
- 230000011664 signaling Effects 0.000 claims 5
- 230000004083 survival effect Effects 0.000 claims 5
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 4
- 229960002707 bendamustine Drugs 0.000 claims 4
- 229960004397 cyclophosphamide Drugs 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 4
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 3
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 3
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 3
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 claims 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000001086 cytosolic effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229960001507 ibrutinib Drugs 0.000 claims 3
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 210000004698 lymphocyte Anatomy 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- -1 4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d] pyrimidin-1-yl Chemical group 0.000 claims 2
- NHHQJBCNYHBUSI-UHFFFAOYSA-N 6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4NC(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 NHHQJBCNYHBUSI-UHFFFAOYSA-N 0.000 claims 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 201000004085 CLL/SLL Diseases 0.000 claims 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 2
- 206010025280 Lymphocytosis Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 238000011394 anticancer treatment Methods 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 2
- 229960001467 bortezomib Drugs 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims 2
- 229960000390 fludarabine Drugs 0.000 claims 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 208000021173 high grade B-cell lymphoma Diseases 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 210000000066 myeloid cell Anatomy 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 229960003347 obinutuzumab Drugs 0.000 claims 2
- 229960002450 ofatumumab Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- 229960003787 sorafenib Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229960000235 temsirolimus Drugs 0.000 claims 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 claims 2
- 229960002110 vincristine sulfate Drugs 0.000 claims 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549067P | 2011-10-19 | 2011-10-19 | |
| US61/549,067 | 2011-10-19 | ||
| PCT/US2012/061208 WO2013059738A2 (en) | 2011-10-19 | 2012-10-19 | Use of inhibitors of bruton's tyrosine kinase (btk) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017174407A Division JP6588515B2 (ja) | 2011-10-19 | 2017-09-11 | ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530877A JP2014530877A (ja) | 2014-11-20 |
| JP2014530877A5 true JP2014530877A5 (enExample) | 2015-12-03 |
| JP6506555B2 JP6506555B2 (ja) | 2019-04-24 |
Family
ID=48141634
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537337A Active JP6506555B2 (ja) | 2011-10-19 | 2012-10-19 | ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用 |
| JP2017174407A Active JP6588515B2 (ja) | 2011-10-19 | 2017-09-11 | ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用 |
| JP2019087022A Active JP6909255B2 (ja) | 2011-10-19 | 2019-04-29 | ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用 |
| JP2021110943A Active JP7366084B2 (ja) | 2011-10-19 | 2021-07-02 | ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用 |
| JP2023175486A Ceased JP2024020199A (ja) | 2011-10-19 | 2023-10-10 | ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017174407A Active JP6588515B2 (ja) | 2011-10-19 | 2017-09-11 | ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用 |
| JP2019087022A Active JP6909255B2 (ja) | 2011-10-19 | 2019-04-29 | ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用 |
| JP2021110943A Active JP7366084B2 (ja) | 2011-10-19 | 2021-07-02 | ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用 |
| JP2023175486A Ceased JP2024020199A (ja) | 2011-10-19 | 2023-10-10 | ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20140303191A1 (enExample) |
| EP (1) | EP2771010A4 (enExample) |
| JP (5) | JP6506555B2 (enExample) |
| KR (5) | KR102054468B1 (enExample) |
| CN (2) | CN104039325A (enExample) |
| AU (5) | AU2012325804B2 (enExample) |
| BR (1) | BR112014009276A8 (enExample) |
| CA (2) | CA2851808C (enExample) |
| EA (2) | EA032463B1 (enExample) |
| IL (4) | IL288009B1 (enExample) |
| MX (2) | MX361772B (enExample) |
| SG (2) | SG10201702913XA (enExample) |
| WO (1) | WO2013059738A2 (enExample) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0906473A8 (pt) | 2008-01-04 | 2016-02-10 | Intellikine Inc | Certas entidades químicas, composições e métodos |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| CN102159214A (zh) | 2008-07-16 | 2011-08-17 | 药品循环公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| US8940725B2 (en) | 2010-05-31 | 2015-01-27 | Ono Pharmaceutical Co., Ltd. | Purinone derivative |
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| PH12013500246A1 (en) | 2010-08-10 | 2019-10-11 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
| JP5956999B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | ヘテロアリール化合物およびその使用 |
| BR112013010564B1 (pt) | 2010-11-01 | 2021-09-21 | Celgene Car Llc | Compostos heterocíclicos e composições compreendendo os mesmos |
| EP2637502B1 (en) | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
| EP3238722B1 (en) | 2011-01-10 | 2019-03-13 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones |
| AU2012255860C1 (en) | 2011-05-17 | 2015-12-10 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| WO2012158795A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| ES2548414T3 (es) | 2011-07-08 | 2015-10-16 | Novartis Ag | Novedosos derivados de pirrolo pirimidina |
| KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| CN103889987B (zh) | 2011-07-19 | 2016-09-14 | 默沙东有限责任公司 | 作为btk抑制剂的选择的咪唑并吡嗪类 |
| DK2734205T3 (en) | 2011-07-21 | 2018-06-14 | Tolero Pharmaceuticals Inc | Heterocyclic Protein Kinase Inhibitors |
| US20140303191A1 (en) * | 2011-10-19 | 2014-10-09 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| JP2014532658A (ja) | 2011-10-28 | 2014-12-08 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | ブルトン型チロシンキナーゼ疾患または障害を治療する方法 |
| BR112014012727B1 (pt) | 2011-11-29 | 2022-10-25 | Ono Pharmaceutical Co., Ltd | Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| WO2014004707A1 (en) * | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| HK1206073A1 (en) | 2012-07-24 | 2015-12-31 | 药品循环有限责任公司 | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| SMT201900344T1 (it) | 2012-09-10 | 2019-07-11 | Principia Biopharma Inc | Composti di pirazolopirimidina come inibitori di chinasi |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| CN105188371A (zh) | 2013-02-08 | 2015-12-23 | 西建阿维拉米斯研究公司 | Erk抑制剂及其用途 |
| PT2970205T (pt) | 2013-03-14 | 2019-08-26 | Tolero Pharmaceuticals Inc | Inibidores da jak2 e da alk2 e métodos para a sua utilização |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| KR20160013204A (ko) | 2013-05-30 | 2016-02-03 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료 |
| CA2920534A1 (en) | 2013-08-12 | 2015-02-19 | Pharmacyclics Llc | Methods for the treatment of her2 amplified cancer |
| US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
| WO2015054197A1 (en) * | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma |
| CA3103411A1 (en) * | 2013-10-25 | 2015-04-30 | Pharmacyclics Llc | Use of ibrutinib for treating and preventing chronic graft versus host disease |
| US11123359B2 (en) | 2013-11-06 | 2021-09-21 | Mayo Foundation For Medical Education And Research | Methods and materials for treating hematological malignancies |
| CA2926893C (en) * | 2013-11-07 | 2022-04-12 | F. Hoffmann-La Roche Ag | Combination therapy of an anti cd20 antibody with a btk inhibitor |
| WO2015071432A1 (en) * | 2013-11-14 | 2015-05-21 | Sandoz Ag | Pharmaceutical compositions of ibrutinib |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| US10314842B2 (en) | 2013-12-02 | 2019-06-11 | Cornell University | Methods for treating B cell proliferative disorders |
| EP3076974A1 (en) | 2013-12-05 | 2016-10-12 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
| CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
| WO2015127261A1 (en) * | 2014-02-21 | 2015-08-27 | Pharmacyclics, Inc. | Biomarkers for predicting response of dlbcl to treatment with ibrutinib |
| US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
| WO2015146159A1 (en) | 2014-03-25 | 2015-10-01 | Ono Pharmaceutical Co., Ltd. | Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma |
| SG10202109752XA (en) * | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| WO2015185998A2 (en) * | 2014-04-11 | 2015-12-10 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase |
| US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| CN104825455B (zh) * | 2014-06-11 | 2017-08-15 | 中国科学院合肥物质科学研究院 | 依鲁替尼的用途 |
| WO2015192081A1 (en) * | 2014-06-13 | 2015-12-17 | Byrd, John C. | Biomarker for predicting response of cll to treatment with a btk inhibitor |
| WO2015193740A2 (en) | 2014-06-17 | 2015-12-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor |
| WO2016010961A1 (en) * | 2014-07-15 | 2016-01-21 | Abbvie Inc. | Enzyme occupancy assay |
| WO2016014859A1 (en) * | 2014-07-25 | 2016-01-28 | Pharmacyclics Llc | Bet inhibitor and bruton's tyrosine kinase inhibitor combinations |
| BR112017001677A2 (pt) * | 2014-08-01 | 2018-07-17 | Pharmacyclics Llc | biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk |
| MX2017001656A (es) * | 2014-08-08 | 2017-07-24 | Pharmacyclics Llc | Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. |
| SMT202100674T1 (it) | 2014-08-11 | 2022-01-10 | Acerta Pharma Bv | Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2 |
| WO2016025561A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Forms and compositions of an erk inhibitor |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| CN104873515B (zh) * | 2014-10-30 | 2017-04-05 | 中国科学院合肥物质科学研究院 | 依鲁替尼对flt3‑itd突变的急性白血病的应用 |
| WO2016071770A2 (en) * | 2014-11-05 | 2016-05-12 | Janssen Pharmaceutica Nv | Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same |
| CN104407067B (zh) * | 2014-11-17 | 2016-01-20 | 广东东阳光药业有限公司 | 依鲁替尼及其异构体的检测方法 |
| WO2016090255A1 (en) * | 2014-12-05 | 2016-06-09 | Sriram Balasubramanian | Biological markers for predicting responsiveness to ibrutinib and r-chop combination therapy and methods of using the same |
| SG11201704808VA (en) | 2014-12-18 | 2017-07-28 | Principia Biopharma Inc | Treatment of pemphigus |
| CA2970043A1 (en) * | 2014-12-23 | 2016-06-30 | Pharmacyclics Llc | Btk inhibitor combinations and dosing regimen |
| HRP20230305T1 (hr) * | 2014-12-24 | 2023-05-26 | Principia Biopharma Inc. | Pripravci za ileo-jejunalnu dostavu lijeka |
| EP3892302B8 (en) * | 2015-04-06 | 2023-10-18 | Janssen Pharmaceutica NV | Compositions containing ibrutinib |
| JP6750613B2 (ja) | 2015-04-09 | 2020-09-02 | 小野薬品工業株式会社 | プリノン誘導体の製造方法 |
| KR20170134462A (ko) | 2015-04-13 | 2017-12-06 | 다이이찌 산쿄 가부시키가이샤 | Mdm2 저해제와 btk 저해제의 병용 치료법 |
| KR101776238B1 (ko) * | 2015-06-12 | 2017-09-12 | 사회복지법인 삼성생명공익재단 | 교모세포종 환자에서 이브루티닙 감수성과 관련된 유전자 및 그 용도 |
| US20180305350A1 (en) | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| IL293821A (en) | 2015-07-02 | 2022-08-01 | Acerta Pharma Bv | Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide |
| EP3747472B1 (en) * | 2015-09-15 | 2024-04-03 | Acerta Pharma B.V. | Therapeutic combinations of a cd19 inhibitor and a btk inhibitor |
| DK3405178T3 (da) * | 2016-01-19 | 2025-09-22 | Janssen Pharmaceutica Nv | Formuleringer/sammensætninger, der omfatter en btk-inhibitor |
| US11813261B2 (en) | 2016-04-19 | 2023-11-14 | Acetylon Pharmaceuticals, Inc. | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia |
| EP3474856B1 (en) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| KR20230047507A (ko) | 2016-06-27 | 2023-04-07 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
| IL263815B (en) | 2016-06-29 | 2022-07-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile |
| US20190240210A1 (en) | 2016-10-17 | 2019-08-08 | Daiichi Sankyo Company, Limited | Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor |
| ES3006132T3 (en) * | 2016-11-15 | 2025-03-17 | Hangzhou Healzen Therapeutics Co Ltd | Selective bruton's tyrosine kinase inhibitor and use thereof |
| EP3658156B1 (en) | 2017-07-28 | 2026-03-25 | Geron Corporation | Telomerase inhibitor for use in treating a myelodysplastic syndrome |
| BR112020020246A8 (pt) | 2018-04-05 | 2022-10-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de cinase axl e uso dos mesmos |
| MX2020010556A (es) | 2018-04-13 | 2021-03-02 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer. |
| KR20210038906A (ko) | 2018-07-26 | 2021-04-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제 |
| CN113631719A (zh) | 2018-11-29 | 2021-11-09 | 美国杰龙生物医药公司 | 治疗骨髓增生异常综合征的方法 |
| HUE072069T2 (hu) | 2019-02-12 | 2025-10-28 | Sumitomo Pharma America Inc | 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| US20220184086A1 (en) * | 2019-03-28 | 2022-06-16 | Cardiff Oncology, Inc. | Plk1 inhibitors and psa levels in prostate cancer |
| AU2020365951B2 (en) | 2019-10-14 | 2026-07-16 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| KR102993352B1 (ko) | 2019-12-20 | 2026-07-22 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021150723A1 (en) | 2020-01-22 | 2021-07-29 | Principia Biopharma Inc. | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| JP2023551679A (ja) * | 2020-12-02 | 2023-12-12 | テリオス ファーマ， インコーポレイテッド | 眼科疾患を治療するための方法及び組成物 |
| CN114681459B (zh) * | 2020-12-29 | 2024-02-27 | 上海云晟研新生物科技有限公司 | 伊布替尼药物组合物、其制备方法及应用 |
| WO2023133444A1 (en) * | 2022-01-07 | 2023-07-13 | University Of Florida Research Foundation, Incorporated | Bruton's tyrosine kinase inhibitors as antiviral agents |
| AU2023372386A1 (en) | 2022-10-31 | 2025-05-08 | Sumitomo Pharma America, Inc. | Pim1 inhibitor for treating myeloproliferative neoplasms |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| EP1307459A2 (en) * | 2000-08-09 | 2003-05-07 | The Regents of the University of California | Indole compounds useful for the treatment of cancer |
| CA2413475C (en) | 2002-04-25 | 2010-07-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Zap-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll) |
| EP2529621B1 (en) * | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| CN101475632B (zh) * | 2008-01-03 | 2012-01-04 | 张喜田 | 具有抗肿瘤作用的重组灵芝免疫调节蛋白及其药物制剂 |
| BRPI0909227B8 (pt) * | 2008-03-25 | 2021-05-25 | Roche Glycart Ag | uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl) |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US20100160322A1 (en) * | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| RU2627588C2 (ru) * | 2010-03-08 | 2017-08-09 | Спектрум Фармасьютикалз, Инк. | Способы лечения рака с применением ингибитора аутофагии на основе тиоксантона |
| MX380504B (es) * | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| US20140303191A1 (en) * | 2011-10-19 | 2014-10-09 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
-
2012
- 2012-10-19 US US14/353,011 patent/US20140303191A1/en not_active Abandoned
- 2012-10-19 WO PCT/US2012/061208 patent/WO2013059738A2/en not_active Ceased
- 2012-10-19 CN CN201280062429.2A patent/CN104039325A/zh active Pending
- 2012-10-19 SG SG10201702913XA patent/SG10201702913XA/en unknown
- 2012-10-19 CA CA2851808A patent/CA2851808C/en active Active
- 2012-10-19 SG SG11201401625TA patent/SG11201401625TA/en unknown
- 2012-10-19 KR KR1020147013035A patent/KR102054468B1/ko active Active
- 2012-10-19 IL IL288009A patent/IL288009B1/en unknown
- 2012-10-19 MX MX2014004647A patent/MX361772B/es active IP Right Grant
- 2012-10-19 BR BR112014009276A patent/BR112014009276A8/pt not_active Application Discontinuation
- 2012-10-19 KR KR1020197035965A patent/KR102258778B1/ko active Active
- 2012-10-19 CA CA3110966A patent/CA3110966A1/en active Pending
- 2012-10-19 EP EP12841068.5A patent/EP2771010A4/en active Pending
- 2012-10-19 EA EA201490798A patent/EA032463B1/ru unknown
- 2012-10-19 KR KR1020257018513A patent/KR20250086805A/ko active Pending
- 2012-10-19 CN CN201911076512.5A patent/CN110801454A/zh active Pending
- 2012-10-19 KR KR1020237023005A patent/KR20230109775A/ko not_active Ceased
- 2012-10-19 EA EA201892766A patent/EA201892766A1/ru unknown
- 2012-10-19 MX MX2017014058A patent/MX391121B/es unknown
- 2012-10-19 IL IL317457A patent/IL317457A/en unknown
- 2012-10-19 AU AU2012325804A patent/AU2012325804B2/en active Active
- 2012-10-19 JP JP2014537337A patent/JP6506555B2/ja active Active
- 2012-10-19 KR KR1020217015880A patent/KR20210065203A/ko not_active Abandoned
-
2014
- 2014-04-10 IL IL232059A patent/IL232059B/en unknown
-
2016
- 2016-12-29 US US15/393,821 patent/US20170266186A1/en not_active Abandoned
-
2017
- 2017-09-11 JP JP2017174407A patent/JP6588515B2/ja active Active
- 2017-12-07 AU AU2017272271A patent/AU2017272271A1/en not_active Abandoned
-
2019
- 2019-04-29 JP JP2019087022A patent/JP6909255B2/ja active Active
- 2019-09-12 AU AU2019229398A patent/AU2019229398B2/en active Active
-
2020
- 2020-02-12 IL IL272622A patent/IL272622A/en unknown
- 2020-12-16 US US17/123,736 patent/US20210361657A1/en not_active Abandoned
-
2021
- 2021-07-02 JP JP2021110943A patent/JP7366084B2/ja active Active
- 2021-12-14 AU AU2021286264A patent/AU2021286264B2/en active Active
-
2023
- 2023-10-10 JP JP2023175486A patent/JP2024020199A/ja not_active Ceased
-
2024
- 2024-05-29 US US18/677,696 patent/US20250127781A1/en active Pending
- 2024-08-09 AU AU2024205662A patent/AU2024205662A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Das et al. | Early B cell changes predict autoimmunity following combination immune checkpoint blockade | |
| Valent et al. | Advances in the classification and treatment of mastocytosis: current status and outlook toward the future | |
| Campàs et al. | Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells | |
| Cho-Vega et al. | Leukemia cutis | |
| AU2010249593B2 (en) | Methods for providing personalized medicine tests ex vivo for hematological neoplasms | |
| Kreitman et al. | Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia | |
| Shanafelt et al. | Ofatumumab‐based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL) | |
| Wang et al. | Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia | |
| Chihara et al. | Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL) | |
| Péron et al. | CD4 lymphopenia to identify end-of-life metastatic cancer patients | |
| JP2016501843A5 (enExample) | ||
| EA201691144A1 (ru) | Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка | |
| JP2016500110A5 (enExample) | ||
| UA122822C2 (uk) | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ | |
| Johnson et al. | Exploration of BRAFV600E as a diagnostic adjuvant in the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) | |
| MX2018014702A (es) | Métodos para predecir el beneficio terapéutico de la terapia con anti-cd19 en pacientes. | |
| Chang et al. | MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides | |
| Maurer et al. | Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia | |
| Yokosuka et al. | Flow cytometric chemosensitivity assay using JC-1, a sensor of mitochondrial transmembrane potential, in acute leukemia | |
| Tse et al. | Expert consensus on the management of chronic lymphocytic leukaemia in Asia | |
| Sośnia et al. | Accelerated chronic lymphocytic leukemia–characteristics and retrospective analysis of the Polish Adult Leukemia Study Group | |
| Sebejova et al. | Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab | |
| AU2020222359A1 (en) | Combination therapy for treatment of B-cell malignancies | |
| Miltiades et al. | Three-fold higher frequency of circulating chronic lymphocytic leukemia-like B-cell clones in patients with Ph-Myeloproliferative neoplasms | |
| Mian et al. | Sequential loss of B‐cell target antigens in multiply relapsed high‐grade B‐cell lymphoma treated with targeted therapies. |